ה-FDA דרש ניסוי נוסף וחברת הביומד הישראלית נסגרה בלעדי
#Customers #Investment
Dec 10, 2020
www.prnewswire.com
Atox Bio Announces FDA Acceptance to File the NDA for Reltecimod to Treat Suspected Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection ("Flesh-Eating Disease")
#Investment
Jul 10, 2020
www.globenewswire.com
Atox Bio Announces a Positive Effect of Reltecimod on Resolution of Organ Dysfunction in Phase 3 ACCUTE Trial for Patients with Necrotizing Soft Tissue Infection ("Flesh Eating Disease")
#Investment
Jun 18, 2019
www.biospace.com
Atox Bio Announces Exercise by BARDA of Next Option Period to Support Continued Development of Reltecimod for NSTI BioSpace
Atox Bio gets $23m for flesh-eating bacteria therapy
#Investment
Dec 19, 2011
www.businesswire.com
Atox Bio Raises $3.25 million to Advance Development of AB103, a Novel Therapy for the Treatment of Severe Bacterial Infections, Currently in Phase 2 Clinical Trials
undefined
Oct 10, 2010
www.integra-holdings.com
Atox Bio raises $2.1 Million to advance development of AB103, a novel therapy for the treatment of severe bacterial infections.
ה-FDA דרש ניסוי נוסף וחברת הביומד הישראלית נסגרה בלעדי
#Customers #Investment
Dec 10, 2020
www.prnewswire.com
Atox Bio Announces FDA Acceptance to File the NDA for Reltecimod to Treat Suspected Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection ("Flesh-Eating Disease")
#Investment
Jul 10, 2020
www.globenewswire.com
Atox Bio Announces a Positive Effect of Reltecimod on Resolution of Organ Dysfunction in Phase 3 ACCUTE Trial for Patients with Necrotizing Soft Tissue Infection ("Flesh Eating Disease")
#Investment
Jun 18, 2019
www.biospace.com
Atox Bio Announces Exercise by BARDA of Next Option Period to Support Continued Development of Reltecimod for NSTI BioSpace
Atox Bio gets $23m for flesh-eating bacteria therapy
#Investment
Dec 19, 2011
www.businesswire.com
Atox Bio Raises $3.25 million to Advance Development of AB103, a Novel Therapy for the Treatment of Severe Bacterial Infections, Currently in Phase 2 Clinical Trials
undefined
Oct 10, 2010
www.integra-holdings.com
Atox Bio raises $2.1 Million to advance development of AB103, a novel therapy for the treatment of severe bacterial infections.